1. Kawasaki T, Kousaki F. Febrile oculo-oro-cutaneo-acrodesquamatous syndrome with or without acute non-suppurative cervical lymphadenitis in infancy and childhood: clinical observations of 50 cases. Jpn J Allergol. 1967; 16:178–222.
2. Manlhiot C, Christie E, McCrindle BW, Rosenberg H, Chahal N, Yeung RS. Complete and incomplete Kawasaki disease: two sides of the same coin. Eur J Pediatr. 2012; 171:657–662.
Article
3. Tewelde H, Yoon J, Van Ittersum W, Worley S, Preminger T, Goldfarb J. The Harada score in the US population of children with Kawasaki disease. Hosp Pediatr. 2014; 4:233–238.
Article
4. Ha KS, Jang GY, Lee J, Lee KC, Son CS. Laboratory markers in incomplete Kawasaki disease according to coronary artery outcome. Korean Circ J. 2018; 48:287–295.
Article
5. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004; 110:2747–2771.
6. Galeotti C, Bayry J, Kone-Paut I, Kaveri SV. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 2010; 9:441–448.
Article
7. Yu X, Hirono KI, Ichida F, et al. Enhanced iNOS expression in leukocytes and circulating endothelial cells is associated with the progression of coronary artery lesions in acute Kawasaki disease. Pediatr Res. 2004; 55:688–694.
Article